Stokes Peebles Archives
Apr. 24, 2023—A Vanderbilt study has found that RSV infection in the first year of life is associated with a significantly increased risk of asthma in children.
Mar. 9, 2023—A Vanderbilt study concluded that RSV’s ability to mutate rapidly to escape detection by the body’s immune system makes it more challenging to design and develop vaccines that can stop it from spreading.
Nov. 10, 2022—VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.
Jul. 21, 2022—A Vanderbilt clinical project will follow 1,950 Middle Tennessee children to determine how genes and the environment interact with RSV infection during the first year of life and contribute to asthma development
Mar. 25, 2021—An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.
Jul. 12, 2018—A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.
Jan. 4, 2018—New findings from Vanderbilt suggest that blocking the migration of cells involved in asthma may represent a new approach for treating the respiratory condition.
Jan. 19, 2017—Investigators in the Division of Allergy, Pulmonary, and Critical Care Medicine and the Division of Diabetes, Endocrinology, and Metabolism recently received a $1.25 million grant from the National Institute of Allergy and Infectious Diseases.
Jul. 21, 2016—Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID).